Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase …

JM Schlaeppi, JM Wood - Cancer and Metastasis Reviews, 1999 - Springer
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an important
mediator of tumor-induced angiogenesis and represents a potential target for innovative …
被引用次数：144 相关文章

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase …

JM Schlaeppi, JM Wood - Cancer and Metastasis Reviews, 1999 - infona.pl
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an important
mediator of tumor-induced angiogenesis and represents a potential target for innovative …

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase …

JM Schlaeppi, JM Wood - Cancer and Metastasis Reviews, 1999 - elibrary.ru
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an important
mediator of tumor-induced angiogenesis and represents a potential target for innovative …

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase …

JM Schlaeppi, JM Wood - Cancer Metastasis Reviews, 1999 - europepmc.org
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an important
mediator of tumor-induced angiogenesis and represents a potential target for innovative …

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase …

JM Schlaeppi, JM Wood - Cancer metastasis reviews, 1999 - pubmed.ncbi.nlm.nih.gov
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an important
mediator of tumor-induced angiogenesis and represents a potential target for innovative …

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase …

JM Schlaeppi, JM Wood - Cancer and Metastasis Reviews, 1999 - search.proquest.com
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an important
mediator of tumorinduced angiogenesis and represents a potential target for innovative …

[引用][C] Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine …

JM SCHLAEPPI, JM WOOD - Cancer metastasis reviews, 1999 - pascal-francis.inist.fr
Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF
neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors CNRS Inist …

[引用][C] Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine …

JM Schlaeppi, JM Wood - Cancer and Metastasis Reviews, 1999 - cir.nii.ac.jp
Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF
neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors | CiNii …

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase …

JM Schlaeppi, JM Wood - Cancer and Metastasis Reviews, 1999 - infona.pl
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is an important
mediator of tumor-induced angiogenesis and represents a potential target for innovative …

[引用][C] Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine …

JM SCHLAEPPI, JM WOOD - Cancer metastasis reviews, 1999 - Springer